ARVO 2025: The first phase 2 study to examine tyrosine kinase inhibitors for wet AMD

At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study. The research she presented focused on neovascular age-related macular degeneration (AMD).

"This is actually the first phase 2 study looking at a tyrosine kinase inhibitor for wet AMD," Dr. Talcott told the Eye Care Network. "This was a sub-analysis of patients looking at how many injections they needed."

Over the course of the study, she said, EYP-1901 was associated with a significant reduction in the amount of injections patients needed to maintaiin visual acuity.

"These are patients who needed, on average, an order of 10 injections in the previous year prior to initiation in the study, and over the course of the study, over 60 percent of them actually did not need any supplemental injections," she said. "[This is] really exciting for our patients in the field of retina, because for neovascular AMD, treatment burden is really a common concern...It was really exciting in the study to see not only that the patient did well, in the study overall, but they might need a lot less frequent treatment."

Dr. Talcott added that a surprising facet of the research was that several patients who previously needed multiple injections did not demonstrate a heightened need in this study. "So these are patients who needed an order of 10 injections in the previous year, and so many of them went without," she said. "If [the patient] had been diagnosed before or after nine months, there was actually no difference if [they] needed supplemental injections."

"It's really impressive that those results were kind of the same among those two groups," she added. Watch the video to hear a full summary of the research findings.